Glenn D. Steele Jr. named chair of City of Hope board of directors

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Glenn D. Steele Jr. was elected board chair of City of Hope, effective June 1.

Steele joined the City of Hope Board of Directors in January 2016. Prior to becoming chair, he was chair of the Executive Compensation and Governance Committee from 2018-2020.

Selwyn Isakow, founder and chief executive officer of The Oxford Investment Group, is the immediate past chair.

His investigations have focused on the cell biology of gastrointestinal cancer and pre-cancer and, most recently, on innovations in health care delivery and financing.

Steele serves as chairman of GSteele Health Solutions, an independently-operated venture launched to help health care organizations create value and improve quality. He is the former chairman of xG Health Solutions and former president and chief executive officer of Geisinger Health System, an integrated health services organization recognized for its innovative use of the electronic health record and the development and implementation of care models.

Steele is past chairman of the American Board of Surgery, and serves on for-profit and not-for-profit boards and national committees, including vice chair of Health Transformation Alliance, Bucknell University Board of Trustees as an emeritus trustee, Stanford Board of Fellows, Peterson Center on Healthcare Advisory Board, and serves as an adviser on the private equity firms of General Atlantic and LRVHealth.

Steele is a member of the National Academy of Medicine and has served as the dean of the Biological Sciences Division and the Pritzker School of Medicine and vice president for medical affairs at University of Chicago, as well as the Richard T. Crane Professor in the Department of Surgery. Prior to that, he was the William V. McDermott Professor of Surgery at Harvard Medical School.

Table of Contents

YOU MAY BE INTERESTED IN

The nagging pain in Mia Sandino’s right knee set in in September 2018, and throughout her freshman year at the University of Washington, she tried to ignore it. “I was being a very naive and invincible-feeling 19-year-old,” Sandino told The Cancer Letter. “I didn’t put two and two together that this area of the knee that...

Rick Pazdur, MD, the newly appointed director for the Center for Drug Evaluation and Research at the FDA, has been described as “greyhound thin” as a result of his dedication to cycling and lifting weights in the gym each day and, for a long time, a vegetarian diet. I first met him when he was the director of the Office of Oncology Drug Products (ODP) within CDER, in 2009.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login